SAB BIOTHERAPEUTICS, INC. Operating Cash Flow
SAB BIOTHERAPEUTICS, INC. (SABS) reported Operating Cash Flow of -$24.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.84M.
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$14.27M.
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$16.78M.
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$13.05M.
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$44.78M.
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$34.29M.
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$25.12M.
- SAB BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$23.46M, a 1280.73% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 2 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$24.11M 10-Q · filed 2026-08-06 | -$40.89M derived: sum of 3 quarters · filed 2026-08-06 | -$53.94M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2026-03-31 | -$14.27M 10-Q · filed 2026-05-12 | -$31.05M derived: sum of 2 quarters · filed 2026-05-12 | -$44.10M derived: sum of 3 quarters · filed 2026-05-12 | -$51.25M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-12-31 | -$16.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$29.83M derived: sum of 2 quarters · filed 2026-03-09 | -$36.98M derived: sum of 3 quarters · filed 2026-08-06 | -$44.78M 10-K · filed 2026-03-09 | |||||
| 2025-09-30 | -$13.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$20.20M derived: sum of 2 quarters · filed 2026-08-06 | -$28.00M 10-Q · filed 2025-11-14 | -$37.53M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-06-30 | -$7.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$14.95M 10-Q · filed 2026-08-06 | -$14.95M 10-Q · filed 2025-08-07 | -$24.48M derived: sum of 3 quarters · filed 2026-08-06 | -$30.77M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$7.80M 10-Q · filed 2026-05-12 | -$17.33M derived: sum of 2 quarters · filed 2026-05-12 | -$23.62M derived: sum of 3 quarters · filed 2026-05-12 | -$31.34M derived: sum of 4 quarters · filed 2026-05-12 | |||||
| 2024-12-31 | -$9.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$15.82M derived: sum of 2 quarters · filed 2026-03-09 | -$23.54M derived: sum of 3 quarters · filed 2026-03-09 | -$34.29M 10-K · filed 2026-03-09 | |||||
| 2024-09-30 | -$6.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$14.01M derived: sum of 2 quarters · filed 2025-11-14 | -$24.76M 10-Q · filed 2025-11-14 | -$38.21M derived: sum of 4 quarters · filed 2025-11-14 | |||||
| 2024-06-30 | -$7.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$18.47M 10-Q · filed 2025-08-07 | -$31.91M derived: sum of 3 quarters · filed 2025-08-07 | -$37.08M derived: sum of 4 quarters · filed 2025-08-07 | |||||
| 2024-03-31 | -$10.75M 10-Q · filed 2025-05-09 | -$24.20M derived: sum of 2 quarters · filed 2025-05-09 | -$29.36M derived: sum of 3 quarters · filed 2025-05-09 | -$34.26M derived: sum of 4 quarters · filed 2025-05-09 | |||||
| 2023-12-31 | -$13.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$18.61M derived: sum of 2 quarters · filed 2025-03-31 | -$23.51M derived: sum of 3 quarters · filed 2025-03-31 | -$25.12M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | -$5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$10.07M derived: sum of 2 quarters · filed 2024-11-06 | -$11.67M 10-Q · filed 2024-11-06 | -$13.23M derived: sum of 4 quarters · filed 2024-11-06 | |||||
| 2023-06-30 | -$4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.50M 10-Q · filed 2024-08-08 | -$8.06M derived: sum of 3 quarters · filed 2024-08-08 | -$15.98M derived: sum of 4 quarters · filed 2024-08-08 | |||||
| 2023-03-31 | -$1.61M 10-Q · filed 2024-05-20 | -$3.16M derived: sum of 2 quarters · filed 2024-05-20 | -$11.08M derived: sum of 3 quarters · filed 2024-05-20 | -$15.53M derived: sum of 4 quarters · filed 2024-05-20 | |||||
| 2022-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$9.47M derived: sum of 2 quarters · filed 2024-03-29 | -$13.92M derived: sum of 3 quarters · filed 2024-03-29 | -$23.46M 10-K · filed 2024-03-29 | |||||
| 2022-09-30 | -$7.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$12.37M derived: sum of 2 quarters · filed 2023-11-13 | -$21.90M 10-Q · filed 2023-11-13 | -$23.68M 10-Q · filed 2022-11-14 | -$26.78M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$4.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$13.99M 10-Q · filed 2023-08-21 | -$15.50M 10-Q · filed 2022-08-10 | -$18.86M derived: sum of 3 quarters · filed 2023-08-21 | -$15.07M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | -$9.54M 10-Q · filed 2023-05-15 | -$10.29M 10-Q · filed 2022-05-12 | -$14.42M derived: sum of 2 quarters · filed 2023-05-15 | -$10.62M derived: sum of 3 quarters · filed 2023-05-15 | -$17.00M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$4.88M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | -$1.08M derived: sum of 2 quarters · filed 2023-04-28 | -$7.47M derived: sum of 3 quarters · filed 2023-04-28 | $1.99M 10-K/A · filed 2023-04-28 | $3.76M 10-K · filed 2022-03-29 | ||||
| 2021-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.59M derived: sum of 2 quarters · filed 2022-11-14 | $6.87M 10-Q · filed 2022-11-14 | -$553.34K 10-Q · filed 2021-11-22 | |||||
| 2021-06-30 | -$6.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $3.07M 10-Q · filed 2022-08-10 | -$464.41K 10-Q · filed 2021-08-09 | ||||||
| 2021-03-31 | $9.45M 10-Q · filed 2022-05-12 | -$363.16K 10-Q · filed 2021-05-21 | |||||||
| 2020-12-31 | -$10.03K 10-K · filed 2021-04-02 | $10.00M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |